{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:34:48Z","timestamp":1791084888039,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"Background<\/jats:title>Prostate cancer (PCa) is a common malignancy occurring in men. As both an endocrine and gonadal organ, prostate is closely correlated with androgen. So, androgen deprivation therapy (ADT) is effective for treating PCa. However, patients will develop castration-resistant prostate cancer (CRPC) stage after ADT. Many other treatments for CRPC exist, including chemotherapy. Vinblastine, a chemotherapeutic drug, is used to treat CRPC. However, patients will develop resistance to vinblastine. Genetic alterations have been speculated to play a critical role in CRPC resistance to vinblastine; however, its mechanism remains unclear.<\/jats:p><\/jats:sec>Methods<\/jats:title>Various databases, such as Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA) and Chinese Prostate Cancer Genome and Epigenome Atlas (CPGEA), were used to collect the RNA-sequence data of PCa and CRPC patients and vinblastine-resistant PCa cells. Using online tools, Metascape and TIMER, the pathways and immune infiltration associated with vinblastine resistance-related genes in PCa were analyzed. The function of these genes was verified in clinical samples and CRPC cells.<\/jats:p><\/jats:sec>Results<\/jats:title>Using GSE81277 dataset, we collected the RNA-sequence data of vinblastine sensitive and resistant LNCaP cells and found nine genes (CDC20<\/jats:italic>, LRRFIP1<\/jats:italic>, CCNB1<\/jats:italic>, GPSM2<\/jats:italic>, AURKA<\/jats:italic>, EBLN2<\/jats:italic>, CCDC150<\/jats:italic>, CENPA<\/jats:italic> and TROAP<\/jats:italic>) that correlated with vinblastine resistance. Furthermore, CCNB1<\/jats:italic>, GPSM2<\/jats:italic> and AURKA<\/jats:italic> were differently expressed between normal prostate and PCa tissues, even influencing PCa progression. The GSE35988 dataset revealed that CCNB1<\/jats:italic> and AURKA<\/jats:italic> were upregulated in PCa and CRPC samples. Various genes were also found to affect the survival status of PCa patients based on TCGA. These genes were also related to immune cell infiltration. Finally, we verified the function of CCNB1<\/jats:italic> and AURKA<\/jats:italic> and observed that they were upregulated in PCa and CRPC clinical samples and increased the sensitivity of CRPC cells to vinblastine.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>CCNB1<\/jats:italic> and AURKA<\/jats:italic> are central to CRPC resistance to vinblastine and affect PCa progression.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.1106175","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T18:05:10Z","timestamp":1671473110000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine"],"prefix":"10.3389","volume":"13","author":[{"given":"Xi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin\u2019an","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duocheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengdang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s12672-022-00508-y","article-title":"Identification of hub genes predicting the development of prostate cancer from benign prostate hyperplasia and analyzing their clinical value in prostate cancer by bioinformatic analysis","volume":"13","author":"Chen","year":"2022","journal-title":"Discovery Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40001-022-00730-y","article-title":"CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer","volume":"27","author":"Chen","year":"2022","journal-title":"Eur J Med Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2010.02.001","article-title":"Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel","volume":"30","author":"Arsov","year":"2012","journal-title":"Urol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4103\/aja.aja_40_17","article-title":"Role of chemotherapy in prostate cancer","volume":"20","author":"Nader","year":"2018","journal-title":"Asian J Androl"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011141611560","article-title":"Phase II study of vinorelbine in patients with androgen-independent prostate cancer","volume":"12","author":"Oudard","year":"2001","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200307000-00011","article-title":"Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer","volume":"9","author":"Koletsky","year":"2003","journal-title":"Cancer J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf029","article-title":"A phase II Hoosier oncology group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer","volume":"13","author":"Sweeney","year":"2002","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the eighth edition of the tumor-Node-Metastasis staging classification for urologic cancers","volume":"73","author":"Paner","year":"2018","journal-title":"Eur Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00128","article-title":"Immune infiltration and prostate cancer","volume":"5","author":"Strasner","year":"2015","journal-title":"Front Oncol"},{"key":"B12","article-title":"Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells","volume":"62","author":"Zegarra-Moro","year":"2002","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-013-9474-0","article-title":"Androgen receptor signaling in prostate cancer","volume":"33","author":"Culig","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23304","article-title":"Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect","volume":"112","author":"Ross","year":"2008","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008315106697","article-title":"Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial","volume":"10","author":"Fields-Jones","year":"1999","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3160","article-title":"Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier oncology group and fox chase network phase III trial","volume":"17","author":"Hudes","year":"1999","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00145-4","article-title":"Vinorelbine in androgen-independent metastatic prostatic carcinoma\u2013a phase II study","volume":"38","author":"Morant","year":"2002","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3892\/or.10.4.885","article-title":"Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer","volume":"10","author":"Robles","year":"2003","journal-title":"Oncol Rep"},{"key":"B19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/030089160308900106","article-title":"Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. a phase II study","volume":"89","author":"Tralongo","year":"2003","journal-title":"Tumori"},{"key":"B20","first-page":"75","article-title":"Combined treatment of androgen-independent prostate cancer cell line DU145 with chemotherapeutic agents and lithium chloride: Effect on growth arrest and\/or apoptosis","volume":"4","author":"Hossein","year":"2012","journal-title":"Avicenna J Med Biotechnol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2017.1356512","article-title":"Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells","volume":"17","author":"Levrier","year":"2018","journal-title":"Cell Cycle"},{"key":"B22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.tcb.2005.11.006","article-title":"Mitosis: a matter of getting rid of the right protein at the right time","volume":"16","author":"Pines","year":"2006","journal-title":"Trends Cell Biol"},{"key":"B23","first-page":"15","article-title":"Expression of the G2-m checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses","volume":"150","author":"Kawamoto","year":"1997","journal-title":"Am J Pathol"},{"key":"B24","article-title":"Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication","volume":"60","author":"Soria","year":"2000","journal-title":"Cancer Res"},{"key":"B25","article-title":"Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma","volume":"62","author":"Hassan","year":"2002","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1569::AID-CNCR19>3.0.CO;2-M","article-title":"The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins a and B1, ki-67, proliferating cell nuclear antigen, and p34cdc2","volume":"85","author":"Kallakury","year":"1999","journal-title":"Cancer"},{"key":"B27","article-title":"Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease","volume":"62","author":"LaTulippe","year":"2002","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23412","article-title":"Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer","volume":"115","author":"Glinsky","year":"2005","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0727","article-title":"Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy","volume":"6","author":"Gomez","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy","volume":"20","author":"Du","year":"2021","journal-title":"Mol Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discovery"},{"key":"B32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ccr.2008.12.005","article-title":"Stabilization of n-myc is a critical function of aurora a in human neuroblastoma","volume":"15","author":"Otto","year":"2009","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1593\/neo.121550","article-title":"Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer","volume":"15","author":"Mosquera","year":"2013","journal-title":"Neoplasia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","article-title":"A phase II trial of the aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: Efficacy and biomarkers","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30073","article-title":"Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora a kinase inhibitor, with docetaxel in patients with solid tumors","volume":"122","author":"Graff","year":"2016","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4161","article-title":"Integrated pan-cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance","volume":"10","author":"Miralaei","year":"2021","journal-title":"Cancer Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cells8010074","article-title":"Application of prostate cancer models for preclinical study: Advantages and limitations of cell lines, patient-derived xenografts, and three-dimensional culture of patient-derived cells","volume":"8","author":"Namekawa","year":"2019","journal-title":"Cells"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1106175\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T18:05:15Z","timestamp":1671473115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1106175\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":37,"alternative-id":["10.3389\/fendo.2022.1106175"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1106175","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"article-number":"1106175"}}